Biotech Wednesday: Guiding cancer treatments in the 21st century
By HollandBio & Oncode
Wednesday, November 25
HollandBIO and Oncode are joining forces to explore what is new in the field of targeted cancer treatments. We are slowly moving away from the ‘one biomarker: one drug’ scenario, which has characterized the first decades of targeted cancer drug development, toward a more integrated approach with multiple biomarkers and drugs.
This ‘new paradigm’ will likely pave the way for the introduction of multiplexing strategies in the clinic using companion diagnostics and patient stratification methodologies. We will cover the frontiering developments from early stage to and clinical studies, clinically validated diagnostics, biomarkers, genomics, and other molecular approaches that are now an indispensable part of 21st century’s cancer treatment.
SPEAKERS & PROGRAM
- Emile Voest – NKI-AVL
- Edwin Cuppen – UMC Utrecht, HMF
- Jeroen de Ridder – UMC Utrecht, Cyclomics
- Caroline van der Meijden – Agendia
- Jos Joore – MIMETAS
- Jeske Timmermans – Roche
- Maroeska Rovers – Health Innovation – Netherlands